eve Conference Detail Block
Conference background
The high-cost and the high risk during the Pharmaceutical R&D process necessitate the development of a Contract Research Organization, i.e. CRO. Pharmaceutical CRO has taken over one-third of the R&D of new drugs all over the world and its market size is growing at an annual rate of 20% to 25%. Although China’s CRO industry had begun to take shape, it is still at the beginning stage. There are over 2000 CROs in China. Most of them are doing simple modifications of dosage forms, imitation drugs or deputy of drug registration. The required market environment for Chinese CRO growth is ready due to incentive policy and regulations, continuing cost advantages and huge rise in space. Under the background of the CRO industry’s system and standard improvement, 2nd Global Pharmaceutical Summit - CRO Forum will be held by Ringier on April 19-20, 2012 in Shanghai. How to attract and enhance professional technicians and management personnel? How to use the resources effectively and participAir Jordan VII 7.5 Ture Flight
Who will attend
By position
Why you need to attend
* Understanding the current industrial development trend in Asia and the rest of the world
* Optimizing the internal resources and outsourcing partnership within and outside China
* Finding opportunities in China’s rapidly developing preclinical and clinical sectors
* Exploring China’s advantages in cost, talent pool and infrastructure support
* Developing new drug disco
Package Plan
Before 29/2/2012: USD 440
After 29/2/2012: USD 540
eve Conference Detail Testimonial
Chinese companies and academics reaching out to the western scientific community through attending meetings, publishing in scientific journals, etc is very important to address this problem. By not publishing more it is not only hurting China's growth but global growth as the opportunity to collaborate on research and find out about new discoveries is limited.
——Seth Goldenberg, President of Asia Pacific Bio Intelligence LLC